In This Article:
The Indian market has stayed flat over the past 7 days but is up 41% over the past year, with earnings expected to grow by 17% annually. In this thriving environment, uncovering hidden gems that show strong potential and align with these growth trends can be particularly rewarding for investors.
Top 10 Undiscovered Gems With Strong Fundamentals In India
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Bharat Rasayan | 8.15% | 0.10% | -7.93% | ★★★★★★ |
| NGL Fine-Chem | 12.95% | 15.22% | 8.68% | ★★★★★★ |
| AGI Infra | 61.29% | 29.13% | 33.44% | ★★★★★★ |
| Knowledge Marine & Engineering Works | 35.48% | 46.55% | 46.96% | ★★★★★★ |
| TCPL Packaging | 95.84% | 15.51% | 31.89% | ★★★★★☆ |
| Kalyani Investment | NA | 21.42% | 6.35% | ★★★★★☆ |
| Magadh Sugar & Energy | 85.41% | 6.65% | 13.60% | ★★★★☆☆ |
| Sky Gold | 127.01% | 22.02% | 48.03% | ★★★★☆☆ |
| Apollo Micro Systems | 38.51% | 10.59% | 11.93% | ★★★★☆☆ |
| SG Mart | 16.77% | 98.09% | 96.54% | ★★★★☆☆ |
Let's review some notable picks from our screened stocks.
Gallantt Ispat
Simply Wall St Value Rating: ★★★★★☆
Overview: Gallantt Ispat Limited engages in the manufacture of iron and steel in India and internationally, with a market cap of ₹86.89 billion.
Operations: Gallantt Ispat generates revenue primarily from the manufacture of iron and steel products. The company has a market cap of ₹86.89 billion.
Gallantt Ispat, a promising player in India's metals sector, reported impressive Q1 2024 earnings with net income at INR 1.22 billion, up from INR 307.19 million last year. The P/E ratio stands at 27.5x, below the Indian market average of 33x, indicating good value. Their net debt to equity ratio is satisfactory at 16.6%, and interest payments are well-covered by EBIT (16.8x). Earnings surged by 115% over the past year, outpacing industry growth of nearly 16%.
-
Unlock comprehensive insights into our analysis of Gallantt Ispat stock in this health report.
-
Examine Gallantt Ispat's past performance report to understand how it has performed in the past.
Marksans Pharma
Simply Wall St Value Rating: ★★★★★★
Overview: Marksans Pharma Limited, along with its subsidiaries, focuses on the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations globally and has a market cap of ₹97.13 billion.
Operations: Marksans Pharma derives its revenue primarily from the sale of generic pharmaceutical formulations. The company has a market cap of ₹97.13 billion and operates globally through its subsidiaries.
Marksans Pharma has shown impressive growth, with earnings up 21.7% over the past year, surpassing industry averages. The company's debt to equity ratio improved from 19.9% to 11.7% in five years, and its EBIT covers interest payments by a robust 32.2 times. Trading at a P/E ratio of 29.1x, it's cheaper than the Indian market average of 33x. Recent quarterly results reported sales of ₹5,906 million and net income of ₹887 million, reflecting solid performance momentum.